Merck & Co ends anti-infective R&D alliance with Ranbaxy
This article was originally published in Scrip
Executive Summary
Merck & Co has ended its R&D collaboration for anti-infectives with Ranbaxy Laboratories, a move seen as fallout from Ranbaxy's changed focus since its acquisition by Japan's Daiichi Sankyo.